Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Natera Inc (NTRA)

Natera Inc (NTRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,740,650
  • Shares Outstanding, K 77,529
  • Annual Sales, $ 257,650 K
  • Annual Income, $ -128,150 K
  • 60-Month Beta 1.35
  • Price/Sales 8.14
  • Price/Cash Flow N/A
  • Price/Book 29.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.60
  • Number of Estimates 3
  • High Estimate -0.49
  • Low Estimate -0.72
  • Prior Year -0.51
  • Growth Rate Est. (year over year) -17.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.55 +12.04%
on 01/03/20
38.25 -7.58%
on 01/17/20
+1.70 (+5.05%)
since 12/27/19
3-Month
31.55 +12.04%
on 01/03/20
40.85 -13.46%
on 11/19/19
-3.27 (-8.47%)
since 10/25/19
52-Week
13.17 +168.41%
on 01/28/19
40.92 -13.61%
on 10/22/19
+21.75 (+159.93%)
since 01/25/19

Most Recent Stories

More News
Natera Files Suit Against ArcherDX for Patent Infringement

Natera, Inc. (NASDAQ: NTRA) a global leader in cell-free DNA testing, filed suit today against ArcherDX for infringement of Natera's U.S. Patent No. 10,538,814 (the "'814 patent"). The complaint was filed...

NTRA : 35.35 (-1.01%)
National Cancer Center Japan Launches Multi-Center Randomized Trial Using Signatera(TM) MRD Testing in Stage II-III Colorectal Cancer

Today Natera, Inc. (NASDAQ: NTRA) announced an agreement with the National Cancer Center (NCC) Japan to launch the CIRCULATE-IDEA trial in Japan, a prospective, multi-center, randomized trial to investigate...

NTRA : 35.35 (-1.01%)
Natera Announces New Early Priority Date cfDNA Patent, Files Suit Against CareDx

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today filed suit against CareDx for infringing its U.S. Patent 10,526,658 ("the '658 patent"). The U.S. Patent Office...

NTRA : 35.35 (-1.01%)
Natera Launches BESPOKE CRC Study to Evaluate Outcomes in 1,000 Signatera(TM) Patients with Stage II-III Colorectal Cancer

Natera, Inc. (NASDAQ: NTRA) a global leader in cell-free DNA testing, today announced a nationwide multi-center registry study called BESPOKE CRC for patients diagnosed with Stage II-III colorectal cancer...

NTRA : 35.35 (-1.01%)
Natera To Webcast Live Presentation at the 38th Annual J.P. Morgan Healthcare Conference

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis...

JPM : 132.75 (+0.55%)
NTRA : 35.35 (-1.01%)
CareDx's False Advertising Complaint Upheld By Court

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant...

NTRA : 35.35 (-1.01%)
CDNA : 23.05 (+6.37%)
Natera Announces Achievement of $55 Million In Pharma Contracts and Issuance of New Oncology Patents

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it has exceeded its 2019 goal of $40-$50 million in cumulative total contract value (TCV) and has expanded its personalized...

NTRA : 35.35 (-1.01%)
First Week of February 21st Options Trading For Natera (NTRA)

Investors in Natera Inc saw new options begin trading this week, for the February 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NTRA options chain for...

NTRA : 35.35 (-1.01%)
SmarTrend Watching for Potential Rebound in Shares of Natera Inc After 3.22% Loss

Natera Inc (NASDAQ:NTRA) traded in a range yesterday that spanned from a low of $33.41 to a high of $34.59. Yesterday, the shares fell 3.2%, which took the trading range below the 3-day low of $34.01...

NTRA : 35.35 (-1.01%)
Natera Receives Final Medicare Coverage for Prospera(TM) Organ Transplant Rejection Assessment Test

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Medicare has finalized its local coverage determination (LCD) to provide insurance coverage for the Prospera...

NTRA : 35.35 (-1.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade NTRA with:

Business Summary

Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California.

See More

Key Turning Points

2nd Resistance Point 36.78
1st Resistance Point 36.07
Last Price 35.35
1st Support Level 34.32
2nd Support Level 33.28

See More

52-Week High 40.92
Last Price 35.35
Fibonacci 61.8% 30.32
Fibonacci 50% 27.04
Fibonacci 38.2% 23.77
52-Week Low 13.17

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar